Postes
24After the interest rate cuts, will dividend stocks win the race in 2025?
Dear stock market players and dividend pearls.
Where will you invest after the interest rate cuts? Bonds!
Or like the Swiss, did you know they have a key interest rate of 0.75%, or dividend favorites and aristocrats:
>4% yields are:
$$
21.11.2024
Nvidia continues to grow explosively thanks to AI boom + DATAGROUP with preliminary figures TOP + Novartis aims for slightly stronger growth in the medium term
The AI boom is a boon for the chip group Nvidia $NVDA (+2,01 %) has become a goldmine - and the business is getting bigger and bigger. In the last quarter, turnover shot up by 94 percent year-on-year to 35.1 billion dollars (33.3 billion euros). Profit more than doubled to 19.3 billion dollars. At the same time, investors had hoped for an even better forecast for the current quarter. The shares of the world's most valuable company, with a market capitalization of around 3.5 trillion dollars, fell by 2.5 percent in US after-hours trading. The AI boom has become a goldmine for the chip company Nvidia - and the business is getting bigger and bigger. In the last quarter, turnover shot up by 94 percent year-on-year to 35.1 billion dollars (33.3 billion euros). Profit more than doubled to 19.3 billion dollars. At the same time, investors had hoped for an even better forecast for the current quarter. The shares of the world's most valuable company, with a market capitalization of around 3.5 trillion dollars, fell by 2.5 percent in US after-hours trading. The next chip generation is on its way!
DATAGROUP $D6H (-2,8 %) reaches the upper end of guidance according to preliminary figures for FY 2023/2024
The Swiss pharmaceutical group Novartis $NOVN (-0,1 %) expects slightly more growth in the medium term than before following its reorganization. In the period from 2023 to 2028, Group sales are expected to increase by an average of 6 percent annually instead of the previously targeted 5 percent, the company announced on Thursday at an investor day. With the new forecast, the Group's top management led by CEO Vasant Narasimhan is relying on the strong growth momentum of the brands already on the market, among other things. Together, these brands have the potential to generate more than 3 to more than 8 billion US dollars a year at peak times. In addition, the Group is about to submit marketing authorization applications for more than 15 additional drugs. The Basel-based company also points to a well-filled research pipeline with more than 30 drugs in testing, which should enable sales growth in the mid-single-digit range even after 2029. Meanwhile, Novartis is still aiming for an adjusted operating margin of more than 40 percent by 2027. The Swiss pharmaceutical giant has now transformed itself into a company specializing purely in innovative medicines. The focus is on the four therapeutic areas of cardiovascular, renal and metabolic diseases, immunology, neurology and oncology
Thursday: Stock market dates, economic data, quarterly figures
ex-dividend of individual stocks
Microsoft USD 0.83
Vodafone Group USD 0.02
Applied Materials USD 0.40
Quarterly figures / company dates USA / Asia
12:30 PDD Holdings quarterly figures
14:00 GE Healthcare Technologies Investor Day
No time specified: Intuit | Gap | Deere & Co quarterly figures | ResMed AGM
Quarterly figures / Company dates Europe
07:00 Julius Baer Group 10 months results
07:30 CTS Eventim quarterly figures
08:00 DFV Deutsche Familienversicherung AG Quarterly figures
Economic data
Earnings summary this morning 👇🏼
$BP. (-0,03 %)
| BP Q3 2024 Earnings
EPS Adj 13.89C (12.67C)
Adj Net $2.27B (est $2.05B)
Oper Cash Flow $6.16B (est $6.29B)
Net Debt $24.21B (est $23.28)
Plans 1.75B Share Buyback For Third Quarter
Sees 4Q Reported Upstream Production To Be Lower Vs Q3
$OMV (-0,69 %) | OMV AG Q3 24 Earnings:
- Clean CCS Oper Profit EU1.10B (est EU1.05B)
- Clean CCS Net Income EU346M (est EU447.8M)
- Still Sees FY Organic CAPEX About EU3.8B (est EU3.68B)
- Sees FY Avg Production 330, 000 To 350, 000 BOE/D
$NOVN (-0,1 %) | Novartis Q3 24 Earnings:
- Core EPS $2.06 (est $1.94)
- Net Sales $12.82B (est 12.68B)
- Net Sales Expected To Grow By 'Double Digit'
- Raises FY Outlook
- Now Sees FY Core Oper Income Growth In High Teens
$SAN (-1,05 %) | Santander Q3 24 Earnings:
- Net Income EU3.35B (est EU3.17B)
- Net Interest Income EU11.23B (est EU11.57B)
- Net Loan - Loss Provision EU2.98B (est EU3.18B)
- Confident It'll Deliver On All Targets
$HSBA (-0,91 %) | HSBC Q3 24 Earnings:
- Div/Shr 10C (est 10C)
- Net Interest Income $7.64B (est $9.25B)
- Sees Div payout Ratio Target Basis of 50% for 2024
- Announces Up $3B Buy Back
$ADS (-0,15 %) | Adidas is optimistic after a strong third quarter and confirms a sales increase of 7.3% to 6.4 billion euros. Demand in Europe and growth in China are driving the development, while profits increase by 73.4% to 469 million euros.
$HYQ (-0,35 %) | Hypoport increases revenue by 29% to 114 million euros in the third quarter and achieves an operating profit of 3.6 million euros, which is above analysts' expectations. The upturn in real estate finance is driving growth.
$LHA (+1,28 %) | Lufthansa announces a savings program to increase adjusted operating profit by EUR 1.5 billion by 2026. Adjusted profit in the third quarter of 2024 falls by 9% to EUR 1.3 billion Deutsche Lufthansa AG expects an operating profit of between EUR 1.4 billion and EUR 1.8 billion for the full year 2024, after focusing on the cost structure in the third quarter. The share is benefiting from hopes of an easing of the Middle East conflict.
$CEC (-2,46 %) | Ceconomy exceeds analysts' expectations with adjusted EBIT in the upper half of the range of 290 to 310 million euros. Sales increase by 5.3% to around 22.4 billion euros in the 2023/2024 financial year
$HFG (+0,69 %) | HelloFresh Group achieves currency-adjusted revenue growth of 1.9% compared to the previous year and adjusted EBITDA ("AEBITDA") of €72 million
Genmab A/S
Company presentation
Genmab A/S is a Danish biotechnology company specializing in the development of innovative therapies to fight cancer. Founded in Copenhagen in 1999, the company is primarily dedicated to the research and production of monoclonal antibodies for oncology treatment. An outstanding product of $GMAB (-0,05 %) is the proprietary Duobody® technology platform, which aims to optimize the treatment of various types of cancer.
Core business and key products
Genmab's core business is the development and commercialization of antibody therapies. Key products include:
Mission and vision
Genmab's mission is to develop innovative and differentiated antibody products that sustainably improve the lives of cancer patients. The company's vision is to be a leader in oncology through pioneering research and development in antibody therapy.
Historical development
Founded in 1999, Genmab went public on the Copenhagen and Frankfurt stock exchanges in 2000. The IPO raised 1.56 billion Danish kroner (approximately 209 million euros) for the company. In 2002, Genmab was delisted again in Frankfurt.
Business model & core competencies
Genmab's business model is based on the development and commercialization of innovative antibody therapies. The company's core competencies lie in the research of monoclonal antibodies and the Duobody® technology platform. This technological expertise gives Genmab a significant competitive advantage in the field of cancer therapies.
Future prospects & strategic initiatives
Genmab is continuously investing in the further development of its antibody technologies and the expansion of its product pipeline. This promising pipeline points to strong growth potential.
Market position & competition
Genmab has established itself as a major player in the field of antibody therapies. The company competes with large pharmaceutical companies such as $ROG (+0,46 %) , $NOVN (-0,1 %) and $GSK (-0,54 %) , with which it also has development and marketing partnerships. Genmab's market position is strengthened by its innovative technologies and strong partnerships.
Total Addressable Market (TAM)
The global market for monoclonal antibodies in cancer therapy is growing steadily. In view of the increasing incidence of cancer and the growing demand for targeted therapies, Genmab has considerable growth potential.
Development
Sales are growing at a CAGR of 31%, while the gross margin is growing at a CAGR of 30%. EBIT shows a fluctuating but increasing development with a CAGR of 20%, and net profit is growing at a CAGR of 22%. The number of shares issued is also falling.
Darzalex is clearly the sales driver and therefore the company's most important product. Nevertheless, the other products are also making progress and growing steadily.
Licensing has enabled the company to maintain a gross margin of 100 % for a long time. However, as it is now beginning to take marketing into its own hands, this margin is expected to decline. At the same time, however, the operating and net profit margins should increase. Overall, however, the margins are encouraging, with a net profit margin of over 25%
SBC has risen well, but remains in line with the company's performance. Moreover, there is no dilution of shares due to the buybacks. The free cash flow (FCF) has also increased solidly, so there is nothing to complain about here.
The shareholder yield is just under 4%. The ratio of enterprise value (EV) to EBITDA falls when EBITDA rises and market capitalization falls. In addition, the ratio of net debt to EBITDA is negative, which is also positive.
Genmab's capital efficiencies are exceptional and are all above 10%.
Conclusion
Genmab A/S, with its focus on innovative antibody therapies and a promising product pipeline, is well positioned to capitalize on the growing opportunities in the field of cancer treatment. The company's solid financial performance and strategic partnerships highlight its potential for future growth and innovation in the biotechnology sector.
Although the share price has fallen recently, Genmab still has significant growth opportunities ahead. The promising pipeline and the upcoming launch of new products are expected to contribute significantly to operating income. In addition, the company has an impressive capital efficiency and benefits from the positive economic situation in Denmark.
Denmark has traditionally established itself as a center for medical technology and biotechnology. The explosive development of companies like Novo Nordisk could also have positive spillover effects for other medical companies, including Genmab. Overall, this is an interesting company that I believe is undervalued based on my DCF analysis.
+ 6
($NOVN (-0,1 %) ) - Novartis clearly exceeds expectations
Things are currently going well for the Basel-based pharmaceutical group.
It has once again raised its forecast for the year. It is now targeting growth in core operating profit in the mid to high teens. Previously, he had assumed an increase in the low double-digit percentage range to the mid-teens. In the second quarter, the SMI Group increased its operating profit by a whopping 43% to $4 billion. The much-noticed core operating profit rose to just under $5 billion and exceeded analysts' expectations. At the bottom line, Novartis earned $3.2 billion. Sales increased by 9% to $12.5 billion. Novartis had already raised its forecast for the year after the first quarter.
Love it.
Happy Investing
GG
18.07.2024 +++ Netflix quarterly figures +++ ECB interest rate decision today +++ VW builds new e-car for China +++ Biden criticizes chip exports to China +++ Novartis raises profit forecast +++ J&J quarterly figures +++ (Update 14:55)
The ECB leaves the key interest rate at 4.25 percent as expected.
The ECB leaves the deposit rate at 3.75 percent as expected.
The ECB leaves the marginal lending rate at 4.5 percent as expected.
ECB: Most inflation indicators remained unchanged or fell slightly in June.
Europe's largest car manufacturer Volkswagen $VOW (+1,96 %) launches a new electric brand for China. Under the new sub-brand ID. Unyx sub-brand, the first car will be launched on the market this summer, said a spokesperson at the world premiere of the first model in Anhui, where it will be produced. Four more are to follow by 2026.
Johnson & Johnson $JNJ (+0,03 %) exceeds analysts' estimates of $2.72 in the second quarter with earnings per share of $2.82. Sales of $22.45 billion exceed expectations of $22.34 billion.
The shares of Nvidia $NVDA (+2,01 %) fell by 4% and the shares of ASML ADRs $ASML (-2,17 %) fell by almost 8% following a Bloomberg report that the Biden administration is considering taking action against companies that export their critical chip manufacturing equipment to China.
The Swiss pharmaceutical company Novartis $NOVN (-0,1 %) has once again raised its profit forecast thanks to good business performance. As the company announced on Thursday, sales in the second quarter amounted to 12.5 billion US dollars. This corresponds to an increase of 9 percent compared to the same period last year. At constant exchange rates, growth amounted to 11 percent. In operating terms, Novartis earned USD 4.0 billion (+43 percent) in the second quarter. The bottom line was a net profit of USD 3.2 billion, compared with USD 2.3 billion in the prior-year period. The increase was mainly due to higher net sales and lower impairments, the statement added
Thursday: Stock market dates, economic data, quarterly figures
Quarterly figures / Company dates USA / Asia
07:30 Taiwan Semiconductor Manufacturing quarterly figures
13:30 Abbott Laboratories quarterly figures
22:00 Netflix quarterly figures
No time specified: KeyCorp | Blackstone Quarterly figures
Quarterly figures / Company dates Europe
07:00 ABB Quarterly figures
07:00 Nokia quarterly figures
07:00 Novartis quarterly figures
07:00 Volvo Car Corp Quarterly figures
07:00 Volvo AB Quarterly figures
10:00 Südzucker AGM
Untimed: Bawag Group quarterly figures
Economic data
Decline in sales expected at $NOVN (-0,1 %)
Novartis AG $NOVN (-0,1 %) is expected to report a decline in quarterly sales when it presents its results for the period ending June 30, 2024 on July 18.
The Basel-based company is expected to report a 9.2% decline in sales to $12.362 billion, compared with $13.62 billion a year ago, according to the median estimate of 10 analysts, based on LSEG data. (Revenue is equal to net sales)
LSEG's mean analyst estimate for Novartis AG is earnings of $1.87 per share.
The current average analyst rating on the stock is Buy with 13 Strong Buy, 13 Hold and 2 Strong Sell recommendations.
The average analysts' earnings estimate has fallen by around 1.0% in the last three months.
The median 12-month Wall Street price target for Novartis AG is CHF 103.00, which is above the last closing price of CHF 99.10.
Hold 16 shares myself, with ~19% price gain and bissel dividend. Stay invested. No matter how the world turns - pharma is always relevant in my opinion.
Happy investing
GG
Source:
Reuters
$NOVN (-0,1 %) In record mood
Quietly, silently and secretly, the Novartis share price has reached triple digits for the first time in recent days.
Last Friday, they reached a record high of 100.72 francs, in line with the market as a whole. The pharmaceutical company will present figures for the second quarter this Thursday.
The majority of analysts assume that the Basel-based company had such a strong quarter that they will once again raise their guidance for the year as a whole. Novartis had already delighted investors with an upgraded guidance when it presented its figures for the first quarter of the year in April. Since then, the share price has been on a steady upward trend. Many analysts believe that the pharmaceutical company is doing many things right.
Source: awp
Own Buy In:
82.96 CHF
$NOVN (-0,1 %) achieves strong effect with blood cancer drug
The pharmaceutical company reports important progress in the Phase III ASC4first study in leukemia. In addition, Scemblix has a favorable safety and tolerability profile.
Novartis can score with another research success. The drug Scemblix was significantly more effective than other treatment approaches in patients with a certain form of blood cancer, Novartis announced on Friday. The Group has now presented the detailed results of the pivotal study at the important oncology congress Asco.
In the Phase III ASC4FIRST study, patients with newly diagnosed leukemia (Ph+ CML-CP) showed a higher response rate after 48 weeks when treated with Scemblix (asciminib) than with the standard tyrosine kinase inhibitors (TKIs) alone selected by the investigators, according to Novartis.
In addition, Scemblix showed a favorable safety and tolerability profile. There were fewer adverse events and treatment discontinuations than with some of the comparator agents.
The efficacy together with the very strong safety and tolerability profile make Scemblix a promising potential first-line option for newly diagnosed patients, the press release continues.
The US Food and Drug Administration (FDA) recently granted the drug breakthrough therapy status in the current indication. Scemblix is already approved in more than 70 countries, including the USA and the EU. It can be used to treat adults with Ph+ CML-CP who have previously been treated with two or more TKIs. In some countries, including the US, Scemblix is also approved for patients with Ph+ CML-CP with a certain mutation (T315I).
Source: AWP/FuW, 31.05.2024
Hello everyone
I wonder if the display of the dividend, or rather the tax, can be adjusted on Getquin?
I live in Switzerland and I pay 35% withholding tax on dividends from Swiss shares, for example. If I declare the dividends on my tax return, I get this amount back in full and then simply pay income tax on it according to my total taxable income.
Getquin only shows me the actual distribution of 65%, which in my view distorts the result somewhat. How is it with you? How is it in Germany?
$NESN (-0,19 %)
$ROG (+0,46 %)
$NOVN (-0,1 %)
$ZURN (-0,89 %)
$SMICHA (-0,07 %)
Meilleurs créateurs cette semaine
